Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating obinutuzumab versus placebo in lupus nephritis has completed, with results posted in February 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis

Drugs mentioned

• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Lupus Nephritis | Phase 2 | Status: COMPLETED | Results posted: 2020-02-26